Amalgamated Bank’s Oramed Pharmaceuticals ORMP Stock Holding History

Amalgamated Bank’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-6,457	Closed	-$56K	–	3154
2022 Q1	$56K	Buy	+6,457	New	+$66.2K	﹤0.01%	2426

Other funds holding ORMP

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

JSMC

Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Amalgamated Bank's ORMP Position: Q2 2022 in Review

Amalgamated Bank sold out of Oramed Pharmaceuticals (ORMP) in Q2 2022, closing a stake of 6,457 shares — an estimated $56K sold.

Amalgamated Bank first reported a position in ORMP in Q1 2022 and held it in 1 quarter. The position peaked at $56K in Q1 2022. 88 funds tracked by Wall St. Rank hold ORMP as of Q2 2022.

Amalgamated Bank reported no remaining Oramed Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Amalgamated Bank sold 6,457 Oramed Pharmaceuticals shares in Q2 2022, an estimated $56K.
Amalgamated Bank first reported a position in Oramed Pharmaceuticals in Q1 2022 and held it in 1 quarter.
Amalgamated Bank's Oramed Pharmaceuticals position peaked at $56K in Q1 2022.
88 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2022.

Based on Amalgamated Bank's 13F filing for Q2 2022, filed 15 Aug 2022.